

Maria Fleseriu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2052470/publications.pdf>

Version: 2024-02-01

250
papers

8,045
citations

66343

42
h-index

64796

79
g-index

316
all docs

316
docs citations

316
times ranked

4266
citing authors

#	ARTICLE	IF	CITATIONS
1	Delayed cerebral ischemia associated with surgery for pituitary macroadenomas that express elevated levels of PACAP. <i>Brain Hemorrhages</i> , 2023, 4, 1-5.	1.0	0
2	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. <i>Pituitary</i> , 2022, 25, 64-73.	2.9	7
3	COVID-19 and hypopituitarism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 215-231.	5.7	18
4	Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 10-28.	3.6	48
5	Nonfunctioning Pituitary Microadenomas: Should Imaging Interval be Extended? A Large Single-center Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1231-e1241.	3.6	11
6	Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States. <i>Pituitary</i> , 2022, 25, 296-307.	2.9	17
7	Personalized Medical Treatment of Patients With Acromegaly: A Review. <i>Endocrine Practice</i> , 2022, 28, 321-332.	2.1	13
8	Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience. <i>Pituitary</i> , 2022, 25, 420-432.	2.9	7
9	Response to Letter to the Editor From Asa and Mete: "Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	3.6	0
10	Perioperative Management of a Patient With Cushing Disease. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac010.	0.2	8
11	Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 102-111.	11.4	23
12	Clinical Study and Systematic Review of Pituitary Microadenomas vs. Macroadenomas in Cushing's Disease: Does Size Matter?. <i>Journal of Clinical Medicine</i> , 2022, 11, 1558.	2.4	4
13	Clinical Biology of the Pituitary Adenoma. <i>Endocrine Reviews</i> , 2022, 43, 1003-1037.	20.1	81
14	Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 385-387.	11.4	4
15	Development of a Novel Algorithm to Identify People with High Likelihood of Adult Growth Hormone Deficiency in a US Healthcare Claims Database. <i>International Journal of Endocrinology</i> , 2022, 2022, 1-9.	1.5	1
16	EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e917-e925.	3.6	37
17	A Pituitary Society update to acromegaly management guidelines. <i>Pituitary</i> , 2021, 24, 1-13.	2.9	158
18	Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome. <i>Pituitary</i> , 2021, 24, 104-115.	2.9	20

#	ARTICLE	IF	CITATIONS
19	Pituitary magnetic resonance imaging use in the posttreatment follow-up of secreting pituitary adenomas. , 2021, , 447-455.		2
20	Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era. <i>Endocrine</i> , 2021, 71, 273-280.	2.3	20
21	Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. <i>European Journal of Endocrinology</i> , 2021, 184, 217-229.	3.7	24
22	Glucocorticoid Receptor Antagonism as a New “Remedy” for Insulin Resistance”Not There Yet!. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2447-e2449.	3.6	1
23	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa205.	0.2	31
24	Thromboembolic disease in hypercortisolism. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 330-336.	2.3	4
25	Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands. <i>Frontiers in Endocrinology</i> , 2021, 12, 627711.	3.5	18
26	Cushing’s syndrome Part 2: Advances in Treatment and in Understanding Complications”Impact. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2021, 35, 101523.	4.7	1
27	Pituitary Disorders and COVID-19, Reimagining Care: The Pandemic A Year and Counting. <i>Frontiers in Endocrinology</i> , 2021, 12, 656025.	3.5	9
28	Levoketoconazole in the Treatment of Patients With Cushing’s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 595894.	3.5	15
29	Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. <i>Endocrine</i> , 2021, 73, 658-666.	2.3	11
30	Echocardiographic findings in acromegaly: prevalence of concentric left ventricular remodeling in a large single-center cohort. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2665-2674.	3.3	5
31	A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands. <i>Journal of the Endocrine Society</i> , 2021, 5, A517-A517.	0.2	3
32	One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly. <i>Journal of the Endocrine Society</i> , 2021, 5, A515-A516.	0.2	2
33	Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy. <i>Journal of the Endocrine Society</i> , 2021, 5, A518-A519.	0.2	2
34	The Pharmacological Burden of Comorbidities in Acromegaly. <i>Journal of the Endocrine Society</i> , 2021, 5, A649-A650.	0.2	2
35	Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands”Results From the MPOWERED Trial. <i>Journal of the Endocrine Society</i> , 2021, 5, A522-A523.	0.2	0
36	Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study. <i>Journal of the Endocrine Society</i> , 2021, 5, A526-A526.	0.2	4

#	ARTICLE	IF	CITATIONS
37	Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial. <i>Journal of the Endocrine Society</i> , 2021, 5, A520-A521.	0.2	2
38	Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly. <i>Journal of the Endocrine Society</i> , 2021, 5, A527-A528.	0.2	1
39	Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD). <i>Journal of the Endocrine Society</i> , 2021, 5, A519-A520.	0.2	1
40	MANAGEMENT OF ENDOCRINE DISEASE: Cardiovascular risk assessment, thromboembolism, and infection prevention in Cushing's syndrome: a practical approach. <i>European Journal of Endocrinology</i> , 2021, 184, R207-R224.	3.7	26
41	Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing's Disease: Final Results From the LINC 2 Study. <i>Journal of the Endocrine Society</i> , 2021, 5, A521-A522.	0.2	5
42	Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. <i>Pituitary</i> , 2021, 24, 943-953.	2.9	11
43	Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2021, 16, 159-174.	2.4	8
44	Clinical features and complications of acromegaly at diagnosis are not all the same: data from two large referral centers. <i>Endocrine Connections</i> , 2021, 10, 731-741.	1.9	11
45	Pituitary society expert Delphi consensus: operative workflow in endoscopic transsphenoidal pituitary adenoma resection. <i>Pituitary</i> , 2021, 24, 839-853.	2.9	24
46	What to Do with Incidentally Discovered Pituitary Abnormalities?. <i>Medical Clinics of North America</i> , 2021, 105, 1081-1098.	2.5	5
47	More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. <i>European Journal of Endocrinology</i> , 2021, 185, 525-538.	3.7	32
48	Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome – A practical guide. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2021, 35, 101490.	4.7	23
49	Cushing's syndrome Part 1: Journey to Improving Diagnosis and Outcomes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2021, 35, 101520.	4.7	0
50	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 847-875.	11.4	315
51	Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e100-e107.	3.6	33
52	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e937-e946.	3.6	207
53	Magnetic resonance imaging in the management of prolactinomas; a review of the evidence. <i>Pituitary</i> , 2020, 23, 16-26.	2.9	27
54	Fertility and Pregnancy in Women With Hypopituitarism: A Systematic Literature Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e53-e65.	3.6	24

#	ARTICLE	IF	CITATIONS
55	The tale in evolution: clarity, consistency and consultation, not contradiction and confusion. Pituitary, 2020, 23, 476-477.	2.9	18
56	Updates in the Medical Treatment of Pituitary Adenomas. Hormone and Metabolic Research, 2020, 52, 8-24.	1.5	21
57	Hypercoagulability in Cushing Syndrome, Prevalence of Thrombotic Events: A Large, Single-Center, Retrospective Study. Journal of the Endocrine Society, 2020, 4, bvz033.	0.2	36
58	Salivary Cortisol in the Diagnosis of Cushing Syndrome, Always More Than One!. Journal of the Endocrine Society, 2020, 4, bvaa109.	0.2	3
59	Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes and Endocrinology, 2020, 8, 748-761.	11.4	114
60	A Novel Etiology of Hypophysitis. Endocrinology and Metabolism Clinics of North America, 2020, 49, 387-399.	3.2	13
61	Management of patients with persistent or recurrent Cushing's disease after initial pituitary surgery. Expert Review of Endocrinology and Metabolism, 2020, 15, 321-339.	2.4	16
62	Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas. Frontiers in Endocrinology, 2020, 11, 579606.	3.5	19
63	Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegaly. Pituitary, 2020, 23, 672-680.	2.9	8
64	MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar. Journal of the Endocrine Society, 2020, 4, .	0.2	0
65	Multidisciplinary management of acromegaly: A consensus. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 667-678.	5.7	183
66	Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3785-e3797.	3.6	54
67	MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study. Journal of the Endocrine Society, 2020, 4, .	0.2	3
68	The journey in diagnosis and treatment, from pituitary adenoma to aggressive pituitary tumors. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 201-202.	5.7	7
69	Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective. Pituitary, 2020, 23, 327-337.	2.9	49
70	MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASSMA OPTIMAL Study. Journal of the Endocrine Society, 2020, 4, .	0.2	0
71	Off-Label Use and Misuse of Testosterone, Growth Hormone, Thyroid Hormone, and Adrenal Supplements: Risks and Costs of a Growing Problem. Endocrine Practice, 2020, 26, 340-353.	2.1	21
72	OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASSMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly. Journal of the Endocrine Society, 2020, 4, .	0.2	1

#	ARTICLE	IF	CITATIONS
73	Acromegaly in the elderly patients. <i>Endocrine</i> , 2020, 68, 16-31.	2.3	24
74	An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies. <i>Pituitary</i> , 2020, 23, 347-358.	2.9	20
75	MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	1
76	Updates in rare and not-so-rare complications of acromegaly: focus on respiratory function and quality of life in acromegaly. <i>F1000Research</i> , 2020, 9, 791.	1.6	3
77	Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. <i>Endocrine Connections</i> , 2020, 9, 1178-1190.	1.9	27
78	Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease. <i>European Journal of Endocrinology</i> , 2020, 182, 207-217.	3.7	29
79	Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. <i>European Journal of Endocrinology</i> , 2020, 182, 583.	3.7	36
80	Endocrinology in the time of COVID-19: Management of pituitary tumours. <i>European Journal of Endocrinology</i> , 2020, 183, G17-G23.	3.7	31
81	MON-308 Pituitary Magnetic Resonance Imaging in the Postoperative Follow-Up of Patients with Acromegaly, Less Is More!. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
82	MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
83	MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
84	MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
85	MON-277 Patient Health Questionnaire 9 (PHQ-9) and Barrat Impulsivity Scale (BIS-11); Tools to Identify Side Effects of Dopamine Agonist Treatment in Patients with Pituitary Adenomas. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
86	MON-320 Inter-Rater Reliability of T2 MRI Intensity of Somatotroph Adenomas; Endocrinologists vs. Neuroradiologist Pilot Study. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
87	MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
88	Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study. <i>Frontiers in Endocrinology</i> , 2019, 10, 436.	3.5	13
89	Ipilimumab-induced hypophysitis, a single academic center experience. <i>Pituitary</i> , 2019, 22, 488-496.	2.9	28
90	Functioning Pituitary Adenomas – Current Treatment Options and Emerging Medical Therapies. <i>European Endocrinology</i> , 2019, 15, 30.	1.5	42

#	ARTICLE	IF	CITATIONS
91	Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study. <i>Clinical Endocrinology</i> , 2019, 91, 776-785.	2.4	24
92	Mifepristone Increases Thyroid Hormone Requirements in Patients With Central Hypothyroidism: A Multicenter Study. <i>Journal of the Endocrine Society</i> , 2019, 3, 1707-1714.	0.2	10
93	Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. <i>Pituitary</i> , 2019, 22, 581-593.	2.9	14
94	A tale of pituitary adenomas: to NET or not to NET. <i>Pituitary</i> , 2019, 22, 569-573.	2.9	60
95	Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 855-865.	11.4	60
96	Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience. <i>Pituitary</i> , 2019, 22, 445-455.	2.9	28
97	Medical Management of Cushing's Syndrome: Current and Emerging Treatments. <i>Drugs</i> , 2019, 79, 935-956.	10.9	39
98	The Evaluation of Incidentally Discovered Adrenal Masses. <i>Endocrine Practice</i> , 2019, 25, 178-192.	2.1	53
99	Response to letter to the editor from Professor Jean-François Bonneville. <i>Pituitary</i> , 2019, 22, 103-103.	2.9	0
100	Hypercortisolemia Recurrence in Cushing's Disease; a Diagnostic Challenge. <i>Frontiers in Endocrinology</i> , 2019, 10, 740.	3.5	31
101	Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. <i>Endocrine Reviews</i> , 2019, 40, 268-332.	20.1	226
102	Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a Pituitary Society survey. <i>Pituitary</i> , 2019, 22, 37-45.	2.9	24
103	High prevalence of adrenal insufficiency at diagnosis and headache recovery in surgically resected Rathke's cleft cysts: a large retrospective single center study. <i>Endocrine</i> , 2019, 63, 463-469.	2.3	13
104	OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3). <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	3
105	SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	3
106	Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. <i>European Journal of Endocrinology</i> , 2019, 180, 31-40.	3.7	58
107	Non-functioning pituitary adenomas, not all the same and certainly not boring!. <i>Pituitary</i> , 2018, 21, 109-110.	2.9	4
108	Recombinant growth hormone treatment, osteoporosis and fractures, more complicated than it seems!. <i>Endocrine</i> , 2018, 59, 463-465.	2.3	4

#	ARTICLE	IF	CITATIONS
109	Silent somatotroph pituitary adenomas: an update. <i>Pituitary</i> , 2018, 21, 194-202.	2.9	28
110	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 17-26.	11.4	116
111	Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review. <i>Pituitary</i> , 2018, 21, 32-40.	2.9	53
112	Updates in Diagnosis and Treatment of Acromegaly. <i>European Endocrinology</i> , 2018, 14, 57.	1.5	56
113	Growth hormone deficiency and replacement effect on adult bone mass: A clinical update. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2018, 3, 7-20.	1.4	5
114	Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study. <i>Pituitary</i> , 2018, 21, 454-462.	2.9	30
115	Pituitary-Directed Therapies for Cushing's Disease. <i>Frontiers in Endocrinology</i> , 2018, 9, 164.	3.5	22
116	Hypercoagulability and Risk of Venous Thromboembolic Events in Endogenous Cushing's Syndrome: A Systematic Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2018, 9, 805.	3.5	62
117	Foreword. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, xiii-xv.	3.2	0
118	Acromegaly, a pituitary special issue. <i>Pituitary</i> , 2017, 20, 2-3.	2.9	3
119	Update on adrenal insufficiency: diagnosis and management in pregnancy. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 184-192.	2.3	34
120	Updates in the Genetics of Endocrine Disorders. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, xiii-xiv.	3.2	0
121	Safety and tolerability of pasireotide long-acting release in acromegaly results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. <i>Endocrine</i> , 2017, 55, 247-255.	2.3	37
122	Evaluation and Management of Adrenal Insufficiency in Critically ill Patients: Disease State Review. <i>Endocrine Practice</i> , 2017, 23, 716-725.	2.1	31
123	Cushing's Disease, Refining the Definition of Remission and Recurrence. , 2017, , 225-252.		2
124	Vitamin D Hormone: Where Do We Stand, Where Are We Heading?. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, xiii-xv.	3.2	0
125	Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience. <i>Endocrine</i> , 2017, 58, 528-534.	2.3	31
126	Candida Meningitis After Transsphenoidal Surgery: A Single-Institution Case Series and Literature Review. <i>World Neurosurgery</i> , 2017, 108, 41-49.	1.3	10

#	ARTICLE	IF	CITATIONS
127	Latest Innovations in Biochemical and Imaging Diagnostics in Endocrinology. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, xiii-xv.	3.2	0
128	Pituitary Dysfunction in Systemic Disorders. , 2017, , 365-381.		1
129	Drugs and Pituitary Function. , 2017, , 383-396.		1
130	The role of combination medical therapy in the treatment of acromegaly. <i>Pituitary</i> , 2017, 20, 136-148.	2.9	25
131	Stereotactic Radiation Therapy in Pituitary Adenomas, is it Better than Conventional Radiation Therapy. <i>Acta Endocrinologica</i> , 2017, 13, 476-490.	0.3	19
132	Medical Therapy with Pasireotide in Recurrent Cushing's Disease: Experience of Patients Treated for At Least 1 Year at a Single Center. <i>Frontiers in Endocrinology</i> , 2017, 8, 35.	3.5	5
133	Medical Treatment of Cushing's Disease. , 2017, , 103-123.		3
134	Recent Progress in the Medical Therapy of Pituitary Tumors. <i>Endocrinology and Metabolism</i> , 2017, 32, 162.	3.0	30
135	Pasireotide: a novel treatment for patients with acromegaly. <i>Drug Design, Development and Therapy</i> , 2016, 10, 227.	4.3	27
136	American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Diagnosis of Recurrence in Cushing Disease. <i>Endocrine Practice</i> , 2016, 22, 1436-1448.	2.1	50
137	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Patients With Nonfunctioning Pituitary Adenomas. <i>Neurosurgery</i> , 2016, 79, 521-523.	1.1	38
138	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pretreatment Endocrine Evaluation of Patients With Nonfunctioning Pituitary Adenomas. <i>Neurosurgery</i> , 2016, 79, E527-E529.	1.1	40
139	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Posttreatment Follow-up Evaluation of Patients With Nonfunctioning Pituitary Adenomas. <i>Neurosurgery</i> , 2016, 79, E541-E543.	1.1	34
140	Pediatric Endocrinology. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, xiii-xv.	3.2	0
141	Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study. <i>Endocrine</i> , 2016, 54, 516-523.	2.3	24
142	Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies. <i>Pituitary</i> , 2016, 19, 643-653.	2.9	70
143	Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, xiii-xiv.	3.2	1
144	Obesity. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, xiii-xv.	3.2	1

#	ARTICLE	IF	CITATIONS
145	Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience. <i>Endocrine</i> , 2016, 54, 191-197.	2.3	1
146	Update on medical treatment for Cushing's disease. <i>Clinical Diabetes and Endocrinology</i> , 2016, 2, 16.	2.7	33
147	Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3888-3921.	3.6	601
148	Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. <i>BMC Endocrine Disorders</i> , 2016, 16, 16.	2.2	63
149	Osilodrostat, a potent oral 11 β -hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. <i>Pituitary</i> , 2016, 19, 138-148.	2.9	116
150	Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. <i>Endocrine</i> , 2016, 53, 210-219.	2.3	59
151	Medical treatment of Cushing's Disease. <i>Minerva Endocrinologica</i> , 2016, 41, 324-40.	1.8	3
152	American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Management of Acromegaly Patients: What is the Role of Pre-Operative Medical Therapy?. <i>Endocrine Practice</i> , 2015, 21, 668-673.	2.1	44
153	Medical Treatment of Cushing Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, 51-70.	3.2	23
154	Pituitary-directed medical therapy in Cushing's disease. <i>Pituitary</i> , 2015, 18, 238-244.	2.9	8
155	Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers. <i>Pituitary</i> , 2015, 18, 245-252.	2.9	21
156	Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study. <i>Pituitary</i> , 2015, 18, 701-709.	2.9	19
157	Pituitary Disorders. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, i.	3.2	0
158	Updates and Highlights in Pituitary Medicine. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, xxi-xxiii.	3.2	0
159	Preoperative Lateralization Modalities for Cushing Disease: Is Dynamic Magnetic Resonance Imaging or Cavernous Sinus Sampling More Predictive of Intraoperative Findings?. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2015, 76, 218-224.	0.8	8
160	Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors. <i>European Journal of Endocrinology</i> , 2015, 172, 707-713.	3.7	37
161	Medical treatment of acromegaly in pregnancy, highlights on new reports. <i>Endocrine</i> , 2015, 49, 577-579.	2.3	8
162	Cushing disease: Where do we stand, where are we heading?. <i>Pituitary</i> , 2015, 18, 179-180.	2.9	1

#	ARTICLE	IF	CITATIONS
163	Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 331-338.	11.4	45
164	Discovery of Cushing's Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients. <i>Obesity Surgery</i> , 2015, 25, 2306-2313.	2.1	12
165	Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1242-E1254.	3.6	144
166	Acromegaly, Awareness Is Paramount for Early Diagnosis: Highlights of Diagnosis and Treatment Challenges. , 2015, , 15-26.		0
167	Challenges and pitfalls in the diagnosis of hyperprolactinemia. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014, 58, 9-22.	1.3	55
168	Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3718-3727.	3.6	78
169	Factors Associated with Biochemical Remission after Microscopic Transsphenoidal Surgery for Acromegaly. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2014, 75, 047-052.	0.8	50
170	Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. <i>Journal of Molecular Endocrinology</i> , 2014, 52, R223-R240.	2.5	131
171	Absence of immunostaining for growth hormone in a subset of patients with acromegaly. <i>Pituitary</i> , 2014, 17, 103-108.	2.9	7
172	Insight into cardiovascular risk factors in patients with acromegaly. <i>Endocrine</i> , 2014, 47, 1-2.	2.3	14
173	Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study. <i>Endocrine</i> , 2014, 46, 585-593.	2.3	43
174	Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial. <i>Endocrine</i> , 2014, 46, 577-584.	2.3	22
175	Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study. <i>Pituitary</i> , 2014, 17, 320-326.	2.9	42
176	LCI699, a Potent 11 β -hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1375-1383.	3.6	160
177	<sc>FRAX</sc> score in acromegaly: does it tell the whole story?. <i>Clinical Endocrinology</i> , 2014, 80, 614-616.	2.4	30
178	OR7-7: Pasireotide LAR provides superior efficacy over octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: a phase III, multicenter, randomized study (PAOLA). <i>Growth Hormone and IGF Research</i> , 2014, 24, S20-S21.	1.1	2
179	Treatment of Cushing's disease: a mechanistic update. <i>Journal of Endocrinology</i> , 2014, 223, R19-R39.	2.6	48
180	Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 875-884.	11.4	309

#	ARTICLE	IF	CITATIONS
181	Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 791-799.	3.6	321
182	Polycystic ovarian syndrome and Cushing's syndrome: a persistent diagnostic quandary. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 175, 145-148.	1.1	22
183	Acromegaly: Assessing the Disorder and Navigating the Therapeutic Options for Treatment. <i>Endocrine Practice</i> , 2014, 20, 7-17.	2.1	22
184	Case Report: Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation. <i>F1000Research</i> , 2014, 3, 171.	1.6	2
185	Recent advances in the medical treatment of Cushing's disease. <i>F1000prime Reports</i> , 2014, 6, 18.	5.9	8
186	Advances in the pharmacotherapy of patients with acromegaly. <i>Discovery Medicine</i> , 2014, 17, 329-38.	0.5	10
187	New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy. <i>Journal of Neuro-Oncology</i> , 2013, 114, 1-11.	2.9	28
188	Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing's disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience. <i>Pituitary</i> , 2013, 16, 452-458.	2.9	80
189	Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. <i>Pituitary</i> , 2013, 16, 490-498.	2.9	121
190	Mifepristone: is there a place in the treatment of Cushing's disease?. <i>Endocrine</i> , 2013, 44, 20-32.	2.3	30
191	Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease. <i>Case Reports in Endocrinology</i> , 2013, 2013, 1-5.	0.4	7
192	A New Era of Cushing Disease Therapeutics. <i>Acta Endocrinologica</i> , 2013, 9, 89-96.	0.3	0
193	The role of combination medical therapy in acromegaly. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013, 20, 321-329.	2.3	15
194	A New Therapeutic Approach in the Medical Treatment of Cushing's SYNDROME: GLUCOCORTICOID RECEPTOR BLOCKADE WITH MIFEPRISTONE. <i>Endocrine Practice</i> , 2013, 19, 313-326.	2.1	53
195	Factors Associated with Biochemical Remission after Open Transsphenoidal Surgery for Acromegaly. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2013, 74, .	0.8	0
196	Short-Term Risk of Recurrence of Surgically Treated, Radiotherapy-Naive Pituitary Adenomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2012, 73, .	0.8	0
197	Medical Management of Persistent and Recurrent Cushing Disease. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 653-668.	1.7	30
198	Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2039-2049.	3.6	409

#	ARTICLE	IF	CITATIONS
199	Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?. Pituitary, 2012, 15, 562-570.	2.9	36
200	Medical management of Cushing's disease: what is the future?. Pituitary, 2012, 15, 330-341.	2.9	82
201	Serum IGF-1 In the Diagnosis of Acromegaly and the Profile of Patients with Elevated IGF-1 but Normal Glucose-Suppressed Growth Hormone. Endocrine Practice, 2012, 18, 817-825.	2.1	26
202	Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary, 2011, 14, 80-91.	2.9	57
203	Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary, 2011, 14, 184-193.	2.9	74
204	Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Refractory Cushing Syndrome: Results from the Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing Syndrome (SEISMIC). , 2011, , OR09-5-OR09-5.		1
205	Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary, 2010, 13, 29-38.	2.9	266
206	Normal Hypothalamic-Pituitary-Adrenal Axis by High-Dose Cosyntropin Testing in Patients with Abnormal Response to Low-Dose Cosyntropin Stimulation: A Retrospective Review. Endocrine Practice, 2010, 16, 64-70.	2.1	20
207	Acromegaly: a review of current medical therapy and new drugs on the horizon. Neurosurgical Focus, 2010, 29, E15.	2.3	17
208	Cabergoline-Induced Cerebral Spinal Fluid Leak in a Patient With a Large Prolactinoma and MEN1. , 2010, 20, 198-202.		5
209	Hypothyroidism and Hyperthyroidism. , 2010, , 416-420.e1.		0
210	Diabetes Insipidus, Panhypopituitarism, and Severe Mental Status Deterioration in a Patient with Chordoid Glioma: Case Report and Literature Review. Endocrine Practice, 2009, 15, 240-245.	2.1	18
211	Significant headache improvement after transsphenoidal surgery in patients with small sellar lesions. Journal of Neurosurgery, 2009, 110, 354-358.	1.6	60
212	Relative adrenal insufficiency in critical illness. Endocrine Practice, 2009, 15, 632-640.	2.1	14
213	Cushing's syndrome might be underappreciated in patients seeking bariatric surgery: a plea for screening. Surgery for Obesity and Related Diseases, 2009, 5, 116-119.	1.2	17
214	Relative adrenal insufficiency. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 392-400.	2.3	31
215	Treatment options for Cushing disease after unsuccessful transsphenoidal surgery. Neurosurgical Focus, 2007, 23, 1-7.	2.3	33
216	Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful. Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 323-328.	2.3	22

#	ARTICLE	IF	CITATIONS
217	Failure of successful renal transplant to produce appropriate levels of 1,25-dihydroxyvitamin D. <i>Osteoporosis International</i> , 2007, 18, 363-368.	3.1	31
218	Successful Treatment of Sulfonylurea-Induced Prolonged Hypoglycemia with Use of Octreotide. <i>Endocrine Practice</i> , 2006, 12, 635-640.	2.1	12
219	Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of "hook effect". <i>Journal of Neuro-Oncology</i> , 2006, 79, 41-43.	2.9	52
220	A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
221	Addition of cabergoline to oral octreotide capsules may improve biochemical control in patients with acromegaly who are inadequately controlled with monotherapy. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
222	Osilodrostat is an effective and well-tolerated treatment option for patients with Cushing's disease (CD): Final results from the LINC3 study. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
223	Oral octreotide capsules lowered incidence and improved severity of acromegaly symptoms compared to injectable somatostatin receptor ligands—results from the MPOWERED trial. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
224	Safety results from MPOWERED, a phase 3 trial of oral octreotide capsules in adults with acromegaly. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
225	A double-blind, randomized, placebo-controlled trial of SPI-62 safety and efficacy for the treatment of Cushing's syndrome. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
226	Osilodrostat provides sustained control of urinary free cortisol in patients with Cushing's disease: final results from a prospective, open-label study (LINC 2). <i>Endocrine Abstracts</i> , 0, , .	0.0	0
227	Improved acromegaly patient satisfaction with oral octreotide capsules compared with injectable somatostatin receptor ligands in the MPOWERED trial. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
228	Can the follow-up imaging interval for non-functioning pituitary microadenomas be extended?. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
229	Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, Phase III study. <i>Endocrine Abstracts</i> , 0, , .	0.0	4
230	Metformin-based oral antidiabetic therapy proved effective in hyperglycaemia associated with pasireotide in patients with acromegaly. <i>Endocrine Abstracts</i> , 0, , .	0.0	5
231	Longitudinal assessment of response to treatment with oral octreotide capsules in patients with acromegaly: post-hoc analysis of a phase 3 trial. <i>Endocrine Abstracts</i> , 0, , .	0.0	4
232	Pasireotide alone or in combination with cabergoline effectively controls urinary free cortisol levels: results from a prospective study in patients with Cushing's disease (CAPACITY). <i>Endocrine Abstracts</i> , 0, , .	0.0	5
233	Late-night salivary cortisol (LNSC) levels in a Phase III study of long-acting pasireotide in patients with Cushing's disease (CD). <i>Endocrine Abstracts</i> , 0, , .	0.0	2
234	AcroCOVID: An international survey on care for acromegaly during the COVID-19 era. <i>Endocrine Abstracts</i> , 0, , .	0.0	3

#	ARTICLE	IF	CITATIONS
235	Results from the phase 3, randomized, double-blind, placebo-controlled OPTIMAL study of oral octreotide capsules in adult patients with acromegaly. Endocrine Abstracts, 0, , .	0.0	2
236	Evaluation of late-night salivary cortisol during a Phase III study with pasireotide in patients with Cushing's disease. Endocrine Abstracts, 0, , .	0.0	1
237	Phase III, multicentre, double-blind, randomised withdrawal study of osilodrostat (LCI699) in patients with Cushing's disease: a study design. Endocrine Abstracts, 0, , .	0.0	0
238	Pasireotide long-acting release maintains biochemical control in patients with acromegaly: results from the extension of randomised, Phase III, PAOLA study. Endocrine Abstracts, 0, , .	0.0	0
239	Biochemical control of most patients reverting to injectable long-acting somatostatin receptor ligands is achieved after one dose: Results from the phase 3, randomized, double blind, placebo-controlled optimal study. Endocrine Abstracts, 0, , .	0.0	0
240	Predictors of response to medical therapy with pegvisomant and pasireotide lar in SRLs-resistant acromegaly. Endocrine Abstracts, 0, , .	0.0	0
241	Impact of imputation method on efficacy results from the phase 3 optimal study of oral octreotide capsules in adult patients with acromegaly. Endocrine Abstracts, 0, , .	0.0	0
242	Analysis of adverse events in adult patients with acromegaly receiving oral octreotide capsules: Results from the phase 3, randomized, double-blind, placebo-controlled optimal study. Endocrine Abstracts, 0, , .	0.0	0
243	Levoketoconazole in the treatment of endogenous Cushing's syndrome: Extended evaluation phase results of the SONICS study. Endocrine Abstracts, 0, , .	0.0	1
244	Sustained response to treatment with oral octreotide capsules: Results from the phase 3, randomized, double blind, placebo-controlled optimal study. Endocrine Abstracts, 0, , .	0.0	0
245	IGF-I variability and its association with demographic and clinical characteristics in patients with acromegaly treated with injectable somatostatin receptor ligands (SRLs); results from OPTIMAL, an international prospective phase 3 study. Endocrine Abstracts, 0, , .	0.0	0
246	Patients receiving a range of doses of prior injectable somatostatin receptor ligands respond to oral octreotide in the treatment of acromegaly: Results from the phase 3 optimal study. Endocrine Abstracts, 0, , .	0.0	0
247	Durability of response and gender-based analysis from the LINC3 trial of osilodrostat in the treatment in Cushing's disease. Endocrine Abstracts, 0, , .	0.0	0
248	Withdrawal from long-acting somatostatin receptor ligand injections in adult patients with acromegaly: Results from the phase 3, randomized, double-blind, placebo-controlled optimal study. Endocrine Abstracts, 0, , .	0.0	0
249	Adult growth hormone deficiency: diagnostic and treatment journeys from the patients' perspective. Journal of the Endocrine Society, 0, , .	0.2	2
250	Plain language summary of the MPOWERED trial comparing the effectiveness, safety, and patient experiences' of monthly injections and oral medication used to treat acromegaly. Future Rare Diseases, 0, , .	0.4	0